Irene Gutiérrez-Cañas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7505609/publications.pdf

Version: 2024-02-01

41 papers

1,435 citations

236612 25 h-index 315357 38 g-index

41 all docs

41 docs citations

41 times ranked

1743 citing authors

#	Article	IF	CITATIONS
1	Topical Application of a Peptide Inhibitor of Transforming Growth Factor- $\hat{1}^21$ Ameliorates Bleomycin-Induced Skin Fibrosis. Journal of Investigative Dermatology, 2005, 125, 450-455.	0.3	149
2	Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Research and Therapy, 2005, 7, R1034.	1.6	104
3	VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. Rheumatology, 2006, 45, 527-532.	0.9	79
4	Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis and Rheumatism, 2008, 58, 1086-1095.	6.7	68
5	Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. British Journal of Rheumatology, 2004, 43, 416-422.	2.5	62
6	RNA sensors in human osteoarthritis and rheumatoid arthritis synovial fibroblasts: Immune regulation by vasoactive intestinal peptide. Arthritis and Rheumatism, 2011, 63, 1626-1636.	6.7	59
7	IL-22/IL-22R1 axis and S100A8/A9 alarmins in human osteoarthritic and rheumatoid arthritis synovial fibroblasts. Rheumatology, 2013, 52, 2177-2186.	0.9	59
8	VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal. British Journal of Pharmacology, 2003, 139, 1050-1058.	2.7	57
9	CXCL12 is displayed by rheumatoid endothelial cells through its basic amino-terminal motif on heparan sulfate proteoglycans. Arthritis Research and Therapy, 2006, 8, R43.	1.6	50
10	Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K. Prostate, 2005, 63, 44-55.	1.2	45
11	VIP reverses the expression profiling of TLR4-stimulated signaling pathway in rheumatoid arthritis synovial fibroblasts. Molecular Immunology, 2008, 45, 3065-3073.	1.0	45
12	CXCL12 gene expression is upregulated by hypoxia and growth arrest but not by inflammatory cytokines in rheumatoid synovial fibroblasts. Cytokine, 2011, 53, 184-190.	1.4	44
13	Profile of Matrix-Remodeling Proteinases in Osteoarthritis: Impact of Fibronectin. Cells, 2020, 9, 40.	1.8	43
14	Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. Regulatory Peptides, 2004, 119, 69-75.	1.9	41
15	Peptides Targeting Toll-Like Receptor Signalling Pathways for Novel Immune Therapeutics. Current Pharmaceutical Design, 2010, 16, 1063-1080.	0.9	39
16	New insights into the role of VIP on the ratio of Tâ€cell subsets during the development of autoimmune diabetes. Immunology and Cell Biology, 2010, 88, 734-745.	1.0	39
17	Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors. Cellular Signalling, 2001, 13, 887-894.	1.7	36
18	The Anti-Inflammatory Mediator, Vasoactive Intestinal Peptide, Modulates the Differentiation and Function of Th Subsets in Rheumatoid Arthritis. Journal of Immunology Research, 2018, 2018, 1-11.	0.9	35

#	Article	IF	Citations
19	A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases. International Journal of Molecular Sciences, 2020, 21, 65.	1.8	35
20	Regulation of TLR expression, a new perspective for the role of VIP in immunity. Peptides, 2007, 28, 1825-1832.	1.2	34
21	Healthy and Osteoarthritic Synovial Fibroblasts Produce a Disintegrin and Metalloproteinase with Thrombospondin Motifs 4, 5, 7, and 12. American Journal of Pathology, 2016, 186, 2449-2461.	1.9	33
22	The pathogenic Th profile of human activated memory Th cells in early rheumatoid arthritis can be modulated by VIP. Journal of Molecular Medicine, 2015, 93, 457-467.	1.7	29
23	Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: Implications for rheumatoid arthritis. Brain, Behavior, and Immunity, 2008, 22, 312-317.	2.0	28
24	VIP impairs acquisition of the macrophage proinflammatory polarization profile. Journal of Leukocyte Biology, 2016, 100, 1385-1393.	1.5	28
25	Effect of VIP on the balance between cytokines and master regulators of activated helper T cells. Immunology and Cell Biology, 2012, 90, 178-186.	1.0	27
26	VIP Decreases TLR4 Expression Induced by LPS and TNF-Â Treatment in Human Synovial Fibroblasts. Annals of the New York Academy of Sciences, 2006, 1070, 359-364.	1.8	24
27	Inflammatory Mediators Alter Interleukin-17 Receptor, Interleukin-12 and -23 Expression in Human Osteoarthritic and Rheumatoid Arthritis Synovial Fibroblasts: Immunomodulation by Vasoactive Intestinal Peptide. NeuroImmunoModulation, 2013, 20, 274-284.	0.9	24
28	Vasoactive Intestinal Peptide Maintains the Nonpathogenic Profile of Human Th17-Polarized Cells. Journal of Molecular Neuroscience, 2014, 54, 512-525.	1.1	20
29	VIP Modulates IL-22R1 Expression and Prevents the Contribution of Rheumatoid Synovial Fibroblasts to IL-22-Mediated Joint Destruction. Journal of Molecular Neuroscience, 2014, 52, 10-17.	1.1	19
30	An Overview of VPAC Receptors in Rheumatoid Arthritis: Biological Role and Clinical Significance. Frontiers in Endocrinology, 2019, 10, 729.	1.5	17
31	Mapping the CRF-urocortins system in human osteoarthritic and rheumatoid synovial fibroblasts: Effect of vasoactive intestinal peptide. Journal of Cellular Physiology, 2011, 226, 3261-3269.	2.0	16
32	VIP and CRF reduce ADAMTS expression and function in osteoarthritis synovial fibroblasts. Journal of Cellular and Molecular Medicine, 2016, 20, 678-687.	1.6	12
33	Activation of Th lymphocytes alters pattern expression and cellular location of VIP receptors in healthy donors and early arthritis patients. Scientific Reports, 2019, 9, 7383.	1.6	12
34	Coexpression of AT1 and AT2 receptors by human fibroblasts is associated with resistance to angiotensin II. Peptides, 2005, 26, 1647-1653.	1.2	7
35	Proteomic Analysis of Synovial Fibroblasts and Articular Chondrocytes Co-Cultures Reveals Valuable VIP-Modulated Inflammatory and Degradative Proteins in Osteoarthritis. International Journal of Molecular Sciences, 2021, 22, 6441.	1.8	5
36	Comparative Study of Senescent Th Biomarkers in Healthy Donors and Early Arthritis Patients. Analysis of VPAC Receptors and Their Influence. Cells, 2020, 9, 2592.	1.8	4

#	Article	IF	CITATIONS
37	Enhanced Susceptibility of Galectin-1 Deficient Mice to Experimental Colitis. Frontiers in Immunology, 2021, 12, 687443.	2.2	4
38	The Neuropeptide VIP Limits Human Osteoclastogenesis: Clinical Associations with Bone Metabolism Markers in Patients with Early Arthritis. Biomedicines, 2021, 9, 1880.	1.4	3
39	FRI0016â \in Involvement of runx-2 and \hat{l}^2 -catenin signaling in the production of adamts-7 and adamts-12 in osteoarthritic synovial fibroblasts. , 2017, , .		O
40	SAT0032â€ACTIVATION OF TH LYMPHOCYTES ALTERS THE PATTERN EXPRESSION AND CELLULAR LOCATION OF THE PATTERN EXPRESSION OF THE	OF	0
41	Human CD4+CD45RA+ T Cells Behavior after In Vitro Activation: Modulatory Role of Vasoactive Intestinal Peptide. International Journal of Molecular Sciences, 2022, 23, 2346.	1.8	0